Logo
x

Search

Subscribe Now

Option Agreement

Sutro Signs an Option Agreement with BioNova to Develop and Commercialize STRO-001 for Hematologic Cancers in Greater China

Sutro Signs an Option Agreement with BioNova to Develop and Commercialize STRO-001 for Hematologic Cancers in Greater China

  • October 12, 2021
LogicBio Signs an Option Agreement with Canbridge to Develop Gene Editing Therapies

LogicBio Signs an Option Agreement with Canbridge to Develop Gene Editing Therapies

  • April 28, 2021
Spark Therapeutics Signs an Option Agreement with Senti Bio to Develop Precision Gene Therapies

Spark Therapeutics Signs an Option Agreement with Senti Bio to Develop Precision Gene Therapies

  • April 14, 2021
Boston Signs Out-License and Option Agreement with GSK to Advance Two Programs for Oncology and CNS Disorders

Boston Signs Out-License and Option Agreement with GSK to Advance Two Programs for Oncology and CNS Disorders

  • March 19, 2021
LEO Pharma Signs an Option Agreement with Ubiquigent to Access its Two Novel Therapies

LEO Pharma Signs an Option Agreement with Ubiquigent to Access its Two Novel Therapies

  • October 30, 2019
Eisai Signs a Research and Option Agreement with Numab to Discover and Develop Multi-Specific Antibody Immunotherapies for Cancer

Eisai Signs a Research and Option Agreement with Numab to Discover and Develop Multi-Specific Antibody Immunotherapies for Cancer

  • October 1, 2019
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.